Wiener klinische Wochenschrift

, Volume 124, Supplement 2, pp 74–78 | Cite as

Geriatrische Aspekte bei Diabetes mellitus

  • Joakim Huber
  • Michael Smeikal
  • Monika Lechleitner
  • Peter Fasching
leitlinien für die praxis
  • 184 Downloads

Zusammenfassung

Es besteht eine hohe Inzidenz an Diabetes mellitus Typ 2 bei Über-70-Jährigen in industrialisierten Ländern. Dieser Artikel enthält Empfehlungen für die Diagnose, die Prävention und die Therapieziele in der Behandlung des älteren diabetischen Patienten an Hand der aktuellen Evidenzlage.

Geriatric aspects for the management of Diabetes mellitus

Summary

There is a high incidence of Diabetes mellitus in the elderly population of industrial countries. The present article provides recommendations for the screening, prevention and treatment of elderly diabetic patients according to current scientific evidence.

Notes

Interessenskonflikt

J. H. hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Eli Lilly, Novartis, Novo Nordisk, Pfizer, Servier. M. S. hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Abbott. M. L. hat von folgenden Unternehmen, die auch förderende Mitglieder der ÖDG sind, Honorare erhalten: Astra Zeneca, Bristol-Myers Squibb, Germania Pharmazeutika, GlaxoSmithKline Pharma, Eli Lilly, Medtronic, Merck Sharp&Dome, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda. P. F. hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Abbott, Astra Zeneca, Bayer Health Care, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Germania Pharmazeutika, GlaxoSmithKline Pharma, Eli Lilly, Merck Serono, Merck Sharp&Dohme, Novartis, Novo Nordisk, Pfizer, Roche, sanofi-aventis, Servier, Takeda. Zusätzlich gebe ich an, dass für mich persönlich kein Interessenskonflikt vorliegt. Ich lege offen, dass ich in diesem Zeitraum von den genannten Firmen Honorare für Vorträge und Consulting erhalten habe, bzw. Fortbildungsunterstützung im Rahmen der (dienst)rechtlichen Rahmenbedingungen bezogen habe (Einladung zu Kongressen) bzw. Klinische Studien als PI mit einzelnen Firmen durchgeführt habe bzw. durchführe.

Literatur

  1. 1.
    Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46:182–9.Google Scholar
  2. 2.
    DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26:61–9.CrossRefGoogle Scholar
  3. 3.
    Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000;23:176–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Hauner H, Kurnaz AA, Haastert B, Groschopp C, Feldhoff KH. Undiagnosed diabetes mellitus and metabolic control assessed by HbA(1c) among residents of nursing homes. Exp Clin Endocrinol Diabetes. 2001;109:326–9.PubMedCrossRefGoogle Scholar
  5. 5.
    American Diabetes Association. Standards of medical care in diabetes–2011. Diabetes Care. 34(Suppl 1):11–61.CrossRefGoogle Scholar
  6. 6.
    Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167:921–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Rosenthal MJ, Fajardo M, Gilmore S, Morley JE, Naliboff BD. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care. 1998;21:231–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMedCrossRefGoogle Scholar
  9. 9.
    Jefferis BJ, Whincup PH, Lennon L, Wannamethee SG. Longitudinal associations between changes in physical activity and onset of type 2 diabetes in older British men: the influence of adiposity. Diabetes Care. 2012;35:1876–83.PubMedCrossRefGoogle Scholar
  10. 10.
    Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218–29.PubMedCrossRefGoogle Scholar
  11. 11.
    Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 34:1329–36.Google Scholar
  12. 12.
    Tan HH, McAlpine RR, James P, et al. Diagnosis of type 2 diabetes at an older age: effect on mortality in men and women. Diabetes Care. 2004;27:2797–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Zeyfang A, Braun A. Guidelines “Diabetes mellitus in the elderly”. MMW Fortschr Med. 2009;151:33–5, 37.PubMedGoogle Scholar
  14. 14.
    Siegmund T, Schumm-Draeger PM. Therapie mit oralen Antidiabetika und/oder Insulin im höheren Alter? Diabetologe. 2010;6:560–9.Google Scholar
  15. 15.
    Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25:471–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Gregg EW, Beckles GL, Williamson DF, et al. Diabetes and physical disability among older U.S. adults. Diabetes Care. 2000;23:1272–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Krop JS, Powe NR, Weller WE, Shaffer TJ, Saudek CD, Anderson GF. Patterns of expenditures and use of services among older adults with diabetes. Implications for the transition to capitated managed care. Diabetes Care. 1998;21:747–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006;67:235–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr., Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012;35:787–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.PubMedCrossRefGoogle Scholar
  23. 23.
    Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRefGoogle Scholar
  24. 24.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.CrossRefGoogle Scholar
  25. 25.
    Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012;13:497–502.PubMedCrossRefGoogle Scholar
  26. 26.
    Schernthaner G, et al. Antihypertensive Therapie bei Diabetes mellitus – Leitlinie der österreichischen Diabetesgesellschaft. Wien Klin Wochenschrift. 2012 (In diesem ausgabe).Google Scholar
  27. 27.
    European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–53.Google Scholar
  28. 28.
    Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care. 2004;27(Suppl 1):65–7.CrossRefGoogle Scholar
  29. 29.
    Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRefGoogle Scholar
  31. 31.
    Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–89.PubMedCrossRefGoogle Scholar
  33. 33.
    Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8:405–18.PubMedCrossRefGoogle Scholar
  34. 34.
    Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27:1049–58.PubMedCrossRefGoogle Scholar
  35. 35.
    Stafford S, Elahi D, Meneilly GS. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc. 2011;59:1148–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2012;14:304–14.PubMedCrossRefGoogle Scholar
  37. 37.
    Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13:939–46.PubMedCrossRefGoogle Scholar
  38. 38.
    Braun AK, Kubiak T, Kuntsche J, et al. SGS: a structured treatment and teaching programme for older patients with diabetes mellitus—a prospective randomised controlled multi-centre trial. Age Ageing. 2009;38:390–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Zeyfang A. Practical aspects of diabetes care in the elderly. MMW Fortschr Med. 2009;151:40–2.PubMedGoogle Scholar
  40. 40.
    Scherbaum WA KW, Hader C, Gräf-Gruss R. Für die DGG/ÖGGG „Praxis-Leitlinie: Diabetes im Alter.“ Eur J Geriatr. 2006;8:231–5.Google Scholar

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  • Joakim Huber
    • 1
  • Michael Smeikal
    • 1
  • Monika Lechleitner
    • 2
  • Peter Fasching
    • 1
  1. 1.5. Medizinische Abteilung mit Endokrinologie, Rheumatologie und AkutgeriatrieWilhelminenspital der Stadt WienWienÖsterreich
  2. 2.Landeskrankenhaus HochzirlHochzirlÖsterreich

Personalised recommendations